Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation…
Processa Pharmaceuticals, Inc. announced that the Company has dosed the first patient in its NGC-Capecitabine (combination of PCS6422 and capecitabine) 300 mg dose group. The Processa…
Read More...
Read More...